Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes (HS-IT101) for the Treatment of Advanced Breast Cancer

NCT05505812 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.

NCT NCT05505812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05505812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes (HS-IT101) for the Treatment of Advanced Breast Cancer
Lead sponsor
The Affiliated Hospital of Qingdao University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 8, 2022
Completion date
March 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer